Evidence map›Paper›PMID 25222500›Full record

ArticleBone marrow transplantation2014

Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

E Gomez, R Duléry, C Langlois, V Coiteux, L Terriou, L Magro, J Gauthier, E de Berranger, A Duhamel, I Yakoub-Agha

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

E GomezUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
R DuléryUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
C LangloisCentre d'Etude et de Recherche en Informatique Médicale, Faculté de Médecine Lille 2, Lille, France.
V CoiteuxUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
L TerriouUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
L MagroUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
J GauthierUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
E de BerrangerUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.
A DuhamelCentre d'Etude et de Recherche en Informatique Médicale, Faculté de Médecine Lille 2, Lille, France.
I Yakoub-AghaUnité de Greffe de Cellules Souches Hématopoïétiques, Service des Maladies du Sang, CHRU Lille, Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM with the FLUIM regimen (group A), and 124 received BM (n=22) or PBSC (n=102) with another RIC regimen (group B). Donors were siblings (n=123) or HLA-matched 10/10 unrelated (n=52). Full donor-type chimerism at day 100 was more often recorded in group A (86%) than in group B (62%); P<0.001. There was no difference between the two groups in terms of OS and EFS, acute GVHD, relapse and non-relapse mortality incidence. cGVHD occurred more often in group B (41%) than in group A (23%); P=0.021. In multivariate analysis, the two risk factors associated with the development of cGVHD were conditioning in group B (hazard ratio (HR)=2.871, 95% confidence interval (CI) (1.372-6.006); P=0.005) and CD34(+) count (HR=1.009, 95% CI (1.006-1.011); P<0.001). In conclusion, the FLUIM regimen followed by BM leads to more frequent full-donor chimerism and a reduced incidence of cGVHD without compromising relapse and survival.

Indexed as

Bone Marrow TransplantationStem Cell TransplantationTransplantation ConditioningTransplantation, HomologousAdolescentAdultAgedBone MarrowFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansMaleMelphalanMiddle AgedRecurrencefludarabineMelphalanVidarabine

Identifiers

PMID25222500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.